Mitochondria-derived ROS Bursts Disturb Ca²⁺ Cycling and Induce Abnormal Automaticity in Guinea Pig Cardiomyocytes: a Theoretical Study
Overview
Physiology
Affiliations
Mitochondria are in close proximity to the redox-sensitive sarcoplasmic reticulum (SR) Ca(2+) release [ryanodine receptors (RyRs)] and uptake [Ca(2+)-ATPase (SERCA)] channels. Thus mitochondria-derived reactive oxygen species (mdROS) could play a crucial role in modulating Ca(2+) cycling in the cardiomyocytes. However, whether mdROS-mediated Ca(2+) dysregulation translates to abnormal electrical activities under pathological conditions, and if yes what are the underlying ionic mechanisms, have not been fully elucidated. We hypothesize that pathological mdROS induce Ca(2+) elevation by modulating SR Ca(2+) handling, which activates other Ca(2+) channels and further exacerbates Ca(2+) dysregulation, leading to abnormal action potential (AP). We also propose that the morphologies of elicited AP abnormality rely on the time of mdROS induction, interaction between mitochondria and SR, and intensity of mitochondrial oxidative stress. To test the hypotheses, we developed a multiscale guinea pig cardiomyocyte model that incorporates excitation-contraction coupling, local Ca(2+) control, mitochondrial energetics, and ROS-induced ROS release. This model, for the first time, includes mitochondria-SR microdomain and modulations of mdROS on RyR and SERCA activities. Simulations show that mdROS bursts increase cytosolic Ca(2+) by stimulating RyRs and inhibiting SERCA, which activates the Na(+)/Ca(2+) exchanger, Ca(2+)-sensitive nonspecific cationic channels, and Ca(2+)-induced Ca(2+) release, eliciting abnormal AP. The morphologies of AP abnormality are largely influenced by the time interval among mdROS burst induction and AP firing, dosage and diffusion of mdROS, and SR-mitochondria distance. This study defines the role of mdROS in Ca(2+) overload-mediated cardiac arrhythmogenesis and underscores the importance of considering mitochondrial targets in designing new antiarrhythmic therapies.
Sun W, Zhang J, Li S, Fu W, Liu Y, Liu M Mol Med. 2025; 31(1):42.
PMID: 39905300 PMC: 11792723. DOI: 10.1186/s10020-025-01103-x.
Shi X, He L, Wang Y, Wu Y, Lin D, Chen C Front Cardiovasc Med. 2024; 11:1488207.
PMID: 39534498 PMC: 11554481. DOI: 10.3389/fcvm.2024.1488207.
PITX2 deficiency leads to atrial mitochondrial dysfunction.
Reyat J, Sommerfeld L, OReilly M, Cardoso V, Thiemann E, Khan A Cardiovasc Res. 2024; 120(15):1907-1923.
PMID: 39129206 PMC: 11630043. DOI: 10.1093/cvr/cvae169.
Guidelines for mechanistic modeling and analysis in cardiovascular research.
Colebank M, Oomen P, Witzenburg C, Grosberg A, Beard D, Husmeier D Am J Physiol Heart Circ Physiol. 2024; 327(2):H473-H503.
PMID: 38904851 PMC: 11442102. DOI: 10.1152/ajpheart.00766.2023.
Zeng X, Sun J, Li F, Peng L, Zhang C, Jiang X Antioxid Redox Signal. 2024; 40(16-18):906-925.
PMID: 38251672 PMC: 11554424. DOI: 10.1089/ars.2023.0399.